Rupprecht, Charles (CDC)
Kuzmin, Ivan (CDC)
CDC researchers have developed recombinant lyssaviruses that can be used for the development of an improved, broad-spectrum vaccine against several rabies genotypes. Lyssaviruses are single-stranded RNA viruses that cause rabies and rabies-like diseases in mammals. Currently, there are commercially available vaccines that are considered to be effective against infections from a single viral phylogroup; however, these vaccines confer little or no protection against viruses outside of the phylogroup. The present recombinants have glycoprotein-encoding genes from at least two different lyssaviruses and can be used as pan-lyssaviral vaccines to provide protection against infection by multiple lyssavirus phylogroups.
- Pan-lyssavirus vaccines
- Rabies surveillance and vaccination programs
- Broad-spectrum vaccine potential
- Pan-lyssavirus vaccination tools will be particularly beneficial in endemic and developing regions
- Employs a presently commercialized vaccine backbone/platform, making this innovation easily adaptable for industrial R&D and subsequent large-scale production